Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥12~* \<90 days following Allogeneic Transplantation.~* ANC\>500/ul for 3 consecutive days.~* ≥50% donor cells in all cellular fractions tested.~* No active grade II or higher acute graft versus host disease~* Receiving ≤ 1 mg/kg/day Methylprednisolone or equivalent~* Documentation of morphologic or radiographic remission within 45 days of protocol enrollment~Exclusion Criteria:~* Patients with acute organ dysfunction requiring monitoring in the Intensive Care unit or receiving invasive interventions that may include, Hemodialysis ,CVVHD, or any form of mechanical ventilation including CPAP/BiPap at the time of starting therapy.~* Pregnant or lactating patients and those without a negative pregnancy test.~* Patients must have a life expectancy of at least 3 months.~* Patients must be HIV negative.~* Patients must not be receiving investigational agents for treatment of GVHD.~* Patients with severe veno-occlusive disease as determined by standard criteria.~* Patients with Type 1 Diabetes at the time of initiation of stem cell transplantation.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).